Aviva’s Keros Therapeutics KROS Stock Holding History

Aviva’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,307	Closed	-$379K	–	885
2026 Q1	$379K	Buy	+34,307	New	+$530K	﹤0.01%	810

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Aviva's KROS Position: Q2 2026 in Review

Aviva sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 34,307 shares — an estimated $379K sold.

Aviva first reported a position in KROS in Q1 2026 and held it in 1 quarter. The position peaked at $379K in Q1 2026. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Aviva reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
Aviva sold 34,307 Keros Therapeutics shares in Q2 2026, an estimated $379K.
Aviva first reported a position in Keros Therapeutics in Q1 2026 and held it in 1 quarter.
Aviva's Keros Therapeutics position peaked at $379K in Q1 2026.
133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.